Medication Monitor

Generic Name (Trade Name—Company)
July 20, 2012


(Kyprolis—Onyx Pharmaceuticals)
Proteasome inhibitor approved for multiple myeloma



Treatment of patients with multiple myeloma who have received at least two prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of completion of the last therapy

Approved by FDA on an accelerated basis, carfilzomib produced responses in 23% of patients with a median duration of response of 7.8 months. Common adverse effects observed in more than 30% of study participants were fatigue, low blood cell count and blood platelet levels, shortness of breath, diarrhea, and fever.

Shortness of breath can be severe, and the drug has been linked to heart failure. If these occur, patients should be monitored closely and treatment withheld.

Multiple myeloma is a blood cancer of plasma cells, usually occurring in bone marrow. In 2012, an estimated 21,700 people will be diagnosed with multiple myeloma and 10,710 will die from the disease, according to the American Cancer Society.